F Dx Advisors, Inc. Argenx Se Transaction History

F Dx Advisors, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	BUY	$356.95 - $413.29 $4,640 - $5,372	13 Added 2.4%	554 $218,000
Q4 2023 Feb 12, 2024	BUY	$338.91 - $506.01 $183,350 - $273,751	541 New	541 $206,000
Q3 2019 Nov 07, 2019	SELL	$113.31 - $150.51 $231,832 - $307,943	-2,046 Closed	0 $0
Q2 2019 Jul 19, 2019	BUY	$115.0 - $141.58 $12,995 - $15,998	113 Added 5.85%	2,046 $290,000
Q1 2019 May 14, 2019	BUY	$98.85 - $134.59 $191,077 - $260,162	1,933 New	1,933 $241,000

371

31.4M

303K

429K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $30B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of F Dx Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on F Dx Advisors, Inc. with notifications on news.